Edwards Lifesciences Corp [EW] stock is trading at $82.45, down -1.23%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The EW shares have gain 8.34% over the last week, with a monthly amount glided 7.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on October 29, 2025, when Wolfe Research upgraded its rating to a Peer Perform. Previously, Jefferies upgraded its rating to Buy on October 29, 2025, and kept the price target unchanged to $98. On October 08, 2025, downgrade downgraded it’s rating to Perform. Evercore ISI upgraded its rating to a Outperform but stick to its price target of $88 on October 07, 2025. BTIG Research upgraded its rating to a Buy but $100 remained the price target by the analyst firm on July 29, 2025. Piper Sandler upgraded its rating to Overweight for this stock on April 24, 2025, but kept the price target unchanged to $80. In a note dated January 30, 2025, Stifel upgraded a Buy rating on this stock and boosted its target price from $75 to $90.
Edwards Lifesciences Corp [EW] stock has fluctuated between $64.89 and $84.66 over the past year. Currently, Wall Street analysts expect the stock to reach $92.33 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $82.45 at the most recent close of the market. An investor can expect a potential return of 11.98% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 5.88B for the trailing twelve months, which represents a growth of 14.67%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.25%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.14 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 80.26 points at the first support level, and at 78.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 85.86, and for the 2nd resistance point, it is at 89.28.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 4.68. In addition, the Quick Ratio stands at 3.87 and the Cash Ratio stands at 2.33. Considering the valuation of this stock, the price to sales ratio is 8.23, the price to book ratio is 4.60 and price to earnings (TTM) ratio is 35.15.
Transactions by insiders
Recent insider trading involved Wood Larry L, Former Affiliate, that happened on Oct 16 ’25 when 8950.0 shares were purchased. CVP, TMTT, Chopra Daveen completed a deal on Aug 25 ’25 to sell 2500.0 shares. Meanwhile, Officer Chopra Daveen bought 2500.0 shares on Aug 25 ’25.
